Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

The defects in molecular and cellular processes that constitute the triggers of specific pathologies are referred to as mechanisms of disease. Research in this area is vital for designing ...

The draft guidance spells out the way trial sponsors should structure diversity action plans (DAPs) to increase enrolment of subjects from historically underrepresented communities, something that ...

News and Comment A xanthone-derived antibiotic with a multifaceted mode of action Oluwatosin Q. Orababa Raphael P. Galleh Research Highlights 18 Jun 2025 Nature Microbiology Volume: 10, P: 1558-1559 ...

The obesity drug liraglutide cut migraine days in half in a small trial, though more research is needed to exclude the placebo effect, researchers said.